Comparing two surgical approaches for prostate cancer treatment
Official title: Clinical TrIAL of Approaches to Prostate cAncer suRgery
Run by Weill Medical College of Cornell University · NCT05155501 · Data updated 2026-11-12
This study is testing whether a new type of prostate surgery that spares more tissue can help men with localized prostate cancer have better cancer control and quality of life compared to the standard surgery.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 40 Years to 80 Years |
| Sex | Men only |
| Enrollment | 600 (estimated) |
| Sponsor | Weill Medical College of Cornell University Academic / other |
| Locations | 9 sites (Duarte, California and 8 other locations) |
| Status | Recruiting |
| Started | May 15, 2023 |
| Main results expected | July 2028 |
| Study ends | July 2028 |
| Registry record updated | April 22, 2026 |
| Trial ID | NCT05155501 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adult men aged 40 to 80 who are scheduled for radical prostatectomy due to clinically localized prostate cancer.
✕Probably not a fit
Patients with prior major pelvic surgery or radiotherapy, or those suspected of having lymph node involvement, may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial is a prospective, randomized controlled trial designed to compare the outcomes of pelvic fascia-sparing radical prostatectomy with standard radical prostatectomy in men diagnosed with clinically localized prostate cancer. The study aims to evaluate cancer control and health-related quality of life, focusing on urinary function, sexual function, and risks of complications such as penile shortening and inguinal hernia. Participants will be randomly assigned to one of the two surgical approaches, and outcomes will be assessed through patient questionnaires and medical record reviews.
Why it matters
Potential benefit: If successful, this study could lead to improved surgical outcomes and quality of life for patients undergoing prostate cancer surgery.
How similar studies have gone: Other studies have shown promising results with similar surgical approaches, suggesting potential for success in this trial.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male sex * Age ≥40 years or ≤80 years * Scheduled for radical prostatectomy for clinically localized prostate cancer * Able to read and speak English or Spanish * Willingness to sign informed consent and adhere to the study protocol Exclusion Criteria: * Prior major pelvic surgery or radiotherapy * Suspicion of N1 disease (i.e., any lymph node greater than 1cm in maximal diameter)
Where it's running
-
Beckman Research Institute of City of Hope
Duarte, California, United States Recruiting -
Georgetown University
Washington D.C., District of Columbia, United States Recruiting -
Northwestern University
Chicago, Illinois, United States Recruiting -
Johns Hopkins University
Baltimore, Maryland, United States Recruiting -
Beth Israel Deaconess Medical Center (BIDMC)
Boston, Massachusetts, United States Recruiting -
Hackensack Meridian Health
Hackensack, New Jersey, United States Recruiting
Show 3 more locations
-
NewYork-Presbyterian Queens
Flushing, New York, United States Recruiting -
Memorial Sloan Kettering Cancer Center
New York, New York, United States Recruiting -
Weill Cornell Medicine
New York, New York, United States Recruiting
Study contacts
- Principal investigator: Jim C Hu, MD, MPH — Weill Medical College of Cornell University
- Study coordinator: May Ting, MBS
- Email: mat7051@med.cornell.edu
- Phone: 732-757-2448
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519
This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.
-
PSMA-guided surgery and tissue-resident T cells in node-positive prostate cancer
This study tests whether PSMA-guided surgery can help identify and study tissue-resident T cells in prostate cancer that has spread to lymph nodes.
-
Predictive factors for response to Lu-177 PSMA therapy in metastatic castration-resistant prostate cancer
This study tests whether imaging, dose measurements, and blood tests can predict which men with metastatic castration-resistant prostate cancer will respond to Lu-177 PSMA therapy.
-
Salvage high-dose-rate brachytherapy for locally recurrent prostate cancer
This observational study tests whether salvage HDR brachytherapy can help men with locally recurrent prostate cancer after initial radiotherapy, using advanced imaging and biopsy to guide treatment.
-
Multi-peptide Vaccination and PSMAxCD3 Antibody Therapy for Prostate Cancer with Biochemical Recurrence
This phase 2 trial tests whether a PSMA-targeted bispecific antibody (CC-1), a prostate cancer peptide vaccine (VAC-XS15-PC01), or both can be given safely and help control biochemical recurrence after local therapy in men with prostate cancer.
-
Lutetium-177 Ludotadipep for advanced prostate cancer
This study tests whether adding Lu-177 Ludotadipep to standard care helps men with metastatic castration-resistant prostate cancer live longer without their disease getting worse.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.